Skip to content
Markets
Deals

Pfizer in Talks to Buy Sickle-Cell Drugmaker for $5 Billion, WSJ Reports

Pfizer Inc.'s European Facilities With Drug Maker Soaring On Vaccine
Photographer: Nathan Laine/Bloomberg
Updated on

Pfizer Inc. is in advanced talks to buy Global Blood Therapeutics Inc., the maker of a therapy for sickle-cell disease, for about $5 billion, the Wall Street Journal reported. 

The New York-based drug giant is looking to finalize a deal in the coming days, the Journal reported, citing people familiar with the matter who asked not to be identified. Bloomberg News had reported earlier this week that the biotech was drawing takeover interest from large pharmaceutical companies.